RFK Jr backs compounding of six unapproved peptides in new policy
US health secretary Robert F Kennedy Jr (RFK Jr) has debuted a policy that allows specific licensed professionals to use…
29 Oct 2026
UK Budget light on life sciences but more doors open for biotech startups
The UK Autumn Budget offered little in the way of new measures specifically for the life sciences sector, though incentives for early-stage businesses could help certain biotechs looking to establish…
29 Oct 2026
Enthorin and Rumi sign agreement for FXS therapy
Enthorin Therapeutics has signed an option-to-license agreement with Rumi Therapeutics to advance ENT-7340 for Fragile X syndrome (FXS), as well as other intellectual and developmental disabilities. Under the deal, Rumi…
29 Oct 2026
Formation Bio launches $600m drug development fund
US-based AI-focused pharmaceutical company Formation Bio has launched the Formation Bio Drug Development Accelerator Fund with a capital of $600m aimed at broadening the company's clinical-stage medicines portfolio. The initiative…
28 Oct 2026
Ferring bets on Gameto’s reproductive health solution through $1.38bn takeover
Swiss pharma company Ferring Pharmaceuticals has agreed to acquire startup Gameto for up to $1.38bn as the company looks to bolster its standing in the reproductive health space. At the…
28 Oct 2026
Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal
Astellas Pharma has inked a billion-dollar licensing deal with Australian biotech, Audax Biosciences, which will see the company secure access to an immuno-oncology asset the latter says has shown “best-in-class”…
28 Oct 2026
Anthropic plots IPO amid ongoing foray into drug development
Artificial intelligence (AI) specialist Anthropic has detailed its plans to dive deeper into the world of drug discovery and development as the tech giant plots its debut on the Nasdaq…